Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGuangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase III clinical studyfor BAT2306, a proposed biosesimilar of Cosentyx® (secukinumab). The clinical study is a randomized,double-blind, para...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177) ,a commercial-stage biopharmaceutical company, today announced that dosing hasbegun in a Phase I clinical study to compare the pharmacokinetics and safety ofBAT2606, a proposed biosesimilar of Nucala ® (mepolizumab), toUS-sourc...
Guangzhou,China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), acommercial-stage biopharmaceutical company, announced today the details of its poster presentation at the VaccinesSummit 2022, being held fromOctober 11-13inWashingtonD.C. Bio-Thera will present research andpreclinical resul...
